Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).

被引：0
|
作者：
Jung, Hyun Ae
Jeon, Yeong Jeong
Kim, Jhingook
Park, Sehhoon
Sun, Jong-Mu
Lee, Se-Hoon
Ahn, Jin Seok
Ahn, Myung-Ju
Park, Keunchil
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol,Dept Med, Seoul, South Korea
[2] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac & Cardiovasc Surg, Seoul, South Korea
[3] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Thorac Surg, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Div Hematol Oncol, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.8529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8529
引用
收藏
页数：3
相关论文
共 41 条
  • [21] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [22] Adjuvant Erlotinib (E) Versus Placebo (P) for Completely Resected Stage IB-IIIA EGFR-Positive (IHC/FISH) Non-Small Cell Lung Cancer (NSCLC): RADIANT Results
    Altorki, N. K.
    O'brien, M. E. R.
    Eberhardt, W. E. E.
    Richardson, F. C.
    Wang, J.
    Foley, M. A.
    Horan, J. D.
    Shepherd, F. A.
    Kelly, K.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S2 - S3
  • [23] Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations
    Geng, R.
    Chen, Y.
    Miao, J.
    Liu, H.
    Qin, Y.
    Han, Z.
    Li, S.
    Guan, Y.
    Wu, H.
    Zhao, Y.
    Wang, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S120 - S121
  • [24] Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR plus NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib
    Zhang, Shannon S.
    Ou, Sai-Hong Ignatius
    LUNG CANCER-TARGETS AND THERAPY, 2022, 13 : 23 - 31
  • [25] Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
    Tetsuya Isaka
    Hiroyuki Ito
    Tomoyuki Yokose
    Haruhiro Saito
    Hiroyuki Adachi
    Kotaro Murakami
    Jun Miura
    Noritake Kikunishi
    Yasushi Rino
    BMC Cancer, 22
  • [26] Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status
    Isaka, Tetsuya
    Ito, Hiroyuki
    Yokose, Tomoyuki
    Saito, Haruhiro
    Adachi, Hiroyuki
    Murakami, Kotaro
    Miura, Jun
    Kikunishi, Noritake
    Rino, Yasushi
    BMC CANCER, 2022, 22 (01)
  • [27] Biomarker testing and adjuvant osimertinib use in patients with resectable EGFR-mutated stage IB-IIIA NSCLC: Physician practices, therapy choice, and barriers among US oncologists
    Aggarwal, Puja
    Savill, Kristin M. Zimmerman
    Jeune-Smith, Yolaine
    Jennings-Zhang, Luke
    Bone, Robert
    Kelly, Ronan Joseph
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Adjuvant Osimertinib in Patients With Stage IB to IIIA EGFR Mutation-Positive NSCLC After Complete Tumor Resection: ADAURA China Subgroup Analysis
    Wang, Jie
    Wu, Yi-Long
    Lu, Shun
    Wang, Qun
    Li, Shanqing
    Zhong, Wen-Zhao
    Wang, Qiming
    Li, Wei
    Wang, Buhai
    Chen, Jun
    Cheng, Ying
    Duan, Hongbing
    Li, Gaofeng
    Shan, Li
    Liu, Yangbo
    Liu, Jing
    Huang, Xiangning
    Bolanos, Ana
    He, Jie
    JTO CLINICAL AND RESEARCH REPORTS, 2024, 5 (02):
  • [29] Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
    Herbst, Roy S.
    Wu, Yi-Long
    John, Thomas
    Grohe, Christian
    Majem, Margarita
    Wang, Jie
    Kato, Terufumi
    Goldman, Jonathan W.
    Laktionov, Konstantin
    Kim, Sang-We
    Yu, Chong-Jen
    Vu, Huu Vinh
    Lu, Shun
    Lee, Kye Young
    Mukhametshina, Guzel
    Akewanlop, Charuwan
    de Marinis, Filippo
    Bonanno, Laura
    Domine, Manuel
    Shepherd, Frances A.
    Urban, Damien
    Huang, Xiangning
    Bolanos, Ana
    Stachowiak, Marta
    Tsuboi, Masahiro
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1830 - +
  • [30] Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC br
    Jung, Hyun Ae
    Lim, Jinyeong
    Choi, Yoon-La
    Lee, Se-Hoon
    Joung, Je-Gun
    Jeon, Yeong Jeong
    Choi, Jae Won
    Shin, Sumin
    Cho, Jong Ho
    Kim, Hong Kwan
    Choi, Yong Soo
    Zo, Jae Ill
    Shim, Young Mog
    Park, Sehhoon
    Sun, Jong-Mu
    Ahn, Jin Seok
    Ahn, Myung-Ju
    Han, Joungho
    Park, Woong-Yang
    Kim, Jhingook
    Park, Keunchil
    CLINICAL CANCER RESEARCH, 2022, 28 (19) : 4312 - 4321
12345